Contract Award: $30M to test the EBOLA vaccine in Africa
Medivector Inc., Boston, Massachusetts, was awarded a $30,000,000 contract, for Phase 2 clinical trials for efficacy testing to include any associated data as may be useful for the Investigational New Drug filing of the product Favipiravir which is directed at development of a medical countermeasure against a validated biological warfare agent (Ebola).
Work will be performed in Boston, MA and in Africa, with an estimated completion date of Nov. 14, 2015. Fiscal 2015 research, development, testing and evaluation funds in the amount of $7,900,000 are being obligated at the time of the award. Army Contracting Command, Natick, Massachusetts, is the contracting activity (W911QY-15-C-0011).
ABOUT Medivector Inc.
MediVector has developed a set of software and process-based tools – SocratesSM — that ensure reduction of the cycle time. SocratesSM’s core benefit is earlier monetization of the asset under development through shorter timelines and lower costs. SocratesSM is most effective if applied as a significant part of the development program. SocratesSM tools facilitate three additional processes: